BioCentury
ARTICLE | Finance

$145M raise positions Rallybio to bring first rare disease program into clinic

Pivotal bioVenture leads megaround for biotech helmed by Alexion veterans

May 20, 2020 1:18 AM UTC

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic next half, and to continue its in-licensing spree.

Fellow new investors including Viking Global Investors, TPG Capital’s The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management, Solasta Ventures, Fairview Capital and Mitsui & Co. Global Investment Inc. also participated in the untranched round, as did existing investors 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations...

BCIQ Company Profiles

Rallybio Corp.